A six-month drug treatment is in its row to cure the world’s leading infectious disease, tuberculosis. The treatment modules have been named as BPaMZ and BPaL, and will include tablets and intravenous injections. The clinical trial results have been astonishing. The BPaL treatment has till successfully cured 40 patients (total 69 patients, 29 still to be assessed) who had extreme drug resistance. Whereas BPaMZ is believed to treat TB patients in the first year itself, who have not developed extreme drug resistance. However, mass clinical trials are required to confirm its effectiveness.